# A Study of Galunisertib in Participants With Myelodysplastic Syndromes

> **NCT02008318** · PHASE2,PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 43 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Galunisertib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02008318
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2016-03
- **Final completion:** 2017-09
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2019-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02008318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02008318, "A Study of Galunisertib in Participants With Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02008318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*